Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
14,731
archived clinical trials in
Psychiatric

Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  3/2/2016
Gulfcoast Clinical Research Center
mi
from
Fort Myers, FL
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 3/2/2016
Gulfcoast Clinical Research Center
mi
from
Fort Myers, FL
Click here to add this to my saved trials
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  3/2/2016
Innovative Clinical Research, Inc
mi
from
Lauderhill, FL
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 3/2/2016
Innovative Clinical Research, Inc
mi
from
Lauderhill, FL
Click here to add this to my saved trials
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  3/2/2016
Compass Research, LLC: North Clinic
mi
from
Leesburg, FL
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 3/2/2016
Compass Research, LLC: North Clinic
mi
from
Leesburg, FL
Click here to add this to my saved trials
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  3/2/2016
Florida Clinical Research Center LLC
mi
from
Maitland, FL
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 3/2/2016
Florida Clinical Research Center LLC
mi
from
Maitland, FL
Click here to add this to my saved trials
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  3/2/2016
Scientific Clinical Research
mi
from
North Miami, FL
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 3/2/2016
Scientific Clinical Research
mi
from
North Miami, FL
Click here to add this to my saved trials
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  3/2/2016
Clinical Neuroscience Solutions, Inc
mi
from
Orlando, FL
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 3/2/2016
Clinical Neuroscience Solutions, Inc
mi
from
Orlando, FL
Click here to add this to my saved trials
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  3/2/2016
Miami Research Associates
mi
from
South Miami, FL
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 3/2/2016
Miami Research Associates
mi
from
South Miami, FL
Click here to add this to my saved trials
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  3/2/2016
Neurotrials Research, Inc.
mi
from
Atlanta, GA
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 3/2/2016
Neurotrials Research, Inc.
mi
from
Atlanta, GA
Click here to add this to my saved trials
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  3/2/2016
Capstone Clinical Research
mi
from
Libertyville, IL
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 3/2/2016
Capstone Clinical Research
mi
from
Libertyville, IL
Click here to add this to my saved trials
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  3/2/2016
Goldpoint Clinical Research
mi
from
Indianapolis, IN
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 3/2/2016
Goldpoint Clinical Research
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  3/2/2016
Clinical Trials Technology, Inc
mi
from
Prairie Village, KA
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 3/2/2016
Clinical Trials Technology, Inc
mi
from
Prairie Village, KA
Click here to add this to my saved trials
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  3/2/2016
Cypress Medical Research Center, LLC
mi
from
Wichita, KA
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 3/2/2016
Cypress Medical Research Center, LLC
mi
from
Wichita, KA
Click here to add this to my saved trials
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  3/2/2016
Louisiana Research Associates, Inc.
mi
from
New Orleans, LA
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 3/2/2016
Louisiana Research Associates, Inc.
mi
from
New Orleans, LA
Click here to add this to my saved trials
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  3/2/2016
McLean Hospital
mi
from
Belmont, MA
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 3/2/2016
McLean Hospital
mi
from
Belmont, MA
Click here to add this to my saved trials
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  3/2/2016
Boston Clinical Trials, INC.
mi
from
Boston, MA
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 3/2/2016
Boston Clinical Trials, INC.
mi
from
Boston, MA
Click here to add this to my saved trials
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  3/2/2016
Adams Clinical Trials LLC
mi
from
Watertown, MA
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 3/2/2016
Adams Clinical Trials LLC
mi
from
Watertown, MA
Click here to add this to my saved trials
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  3/2/2016
Rochester Center for Behavioral Medicine
mi
from
Rochester Hills, MI
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 3/2/2016
Rochester Center for Behavioral Medicine
mi
from
Rochester Hills, MI
Click here to add this to my saved trials
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  3/2/2016
HBSA-Pacific Institute for Research & Evaluation
mi
from
Albuquerque, NM
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 3/2/2016
HBSA-Pacific Institute for Research & Evaluation
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  3/2/2016
Brooklyn Medical Institute
mi
from
Brooklyn, NY
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 3/2/2016
Brooklyn Medical Institute
mi
from
Brooklyn, NY
Click here to add this to my saved trials
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  3/2/2016
Wake Research Associates, LLC
mi
from
Raleigh, NC
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 3/2/2016
Wake Research Associates, LLC
mi
from
Raleigh, NC
Click here to add this to my saved trials
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  3/2/2016
Patient Priority Clinical sites, LLC
mi
from
Cincinnati, OH
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 3/2/2016
Patient Priority Clinical sites, LLC
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  3/2/2016
Community Research
mi
from
Cincinnati, OH
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 3/2/2016
Community Research
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  3/2/2016
Midwest Clinical Research Center
mi
from
Dayton, OH
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 3/2/2016
Midwest Clinical Research Center
mi
from
Dayton, OH
Click here to add this to my saved trials
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  3/2/2016
Linder Center of Hope
mi
from
Mason, OH
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 3/2/2016
Linder Center of Hope
mi
from
Mason, OH
Click here to add this to my saved trials
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  3/2/2016
Oregon Center for Clinical Investigations, Inc (OCCI, Inc.)
mi
from
Portland, OR
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 3/2/2016
Oregon Center for Clinical Investigations, Inc (OCCI, Inc.)
mi
from
Portland, OR
Click here to add this to my saved trials
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  3/2/2016
Oregon Center for Clinical Investigations, Inc. (OCCI, Inc.)
mi
from
Salem, OR
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 3/2/2016
Oregon Center for Clinical Investigations, Inc. (OCCI, Inc.)
mi
from
Salem, OR
Click here to add this to my saved trials
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  3/2/2016
Lehigh Center for Clinical Research
mi
from
Allentown, PA
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 3/2/2016
Lehigh Center for Clinical Research
mi
from
Allentown, PA
Click here to add this to my saved trials
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  3/2/2016
Omega Medical Research
mi
from
Warwick, RI
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 3/2/2016
Omega Medical Research
mi
from
Warwick, RI
Click here to add this to my saved trials
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  3/2/2016
Radiant Research, Inc.
mi
from
Anderson, SC
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 3/2/2016
Radiant Research, Inc.
mi
from
Anderson, SC
Click here to add this to my saved trials
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  3/2/2016
Radiant Research
mi
from
Greer, SC
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 3/2/2016
Radiant Research
mi
from
Greer, SC
Click here to add this to my saved trials
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  3/2/2016
Coastal Carolina Research Center
mi
from
Mount Pleasant, SC
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 3/2/2016
Coastal Carolina Research Center
mi
from
Mount Pleasant, SC
Click here to add this to my saved trials
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  3/2/2016
Clinical Neuroscience Solution, Inc
mi
from
Memphis, TN
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 3/2/2016
Clinical Neuroscience Solution, Inc
mi
from
Memphis, TN
Click here to add this to my saved trials
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  3/2/2016
FutureSearch Clinical Trials LP
mi
from
Austin, TX
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 3/2/2016
FutureSearch Clinical Trials LP
mi
from
Austin, TX
Click here to add this to my saved trials
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  3/2/2016
FutureSearch Trials of Dallas, LP
mi
from
Dallas, TX
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 3/2/2016
FutureSearch Trials of Dallas, LP
mi
from
Dallas, TX
Click here to add this to my saved trials
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  3/2/2016
Texas Center for Drug Development, P.A.
mi
from
Houston, TX
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 3/2/2016
Texas Center for Drug Development, P.A.
mi
from
Houston, TX
Click here to add this to my saved trials
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  3/2/2016
Research Across America
mi
from
Plano, TX
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 3/2/2016
Research Across America
mi
from
Plano, TX
Click here to add this to my saved trials
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  3/2/2016
Radiant Research, Inc
mi
from
San Antonio, TX
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 3/2/2016
Radiant Research, Inc
mi
from
San Antonio, TX
Click here to add this to my saved trials
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  3/2/2016
Northwest Clinical Research Center
mi
from
Bellevue, WA
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 3/2/2016
Northwest Clinical Research Center
mi
from
Bellevue, WA
Click here to add this to my saved trials
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  3/2/2016
Summit Research Network (Seattle) LLC
mi
from
Seattle, WA
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 3/2/2016
Summit Research Network (Seattle) LLC
mi
from
Seattle, WA
Click here to add this to my saved trials
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  3/2/2016
Anxiety and Mood Disorder Center
mi
from
Mississauga,
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 3/2/2016
Anxiety and Mood Disorder Center
mi
from
Mississauga,
Click here to add this to my saved trials
Functional Brain Imaging in PTSD
Functional Brain Imaging in PTSD
Status: Enrolling
Updated:  3/2/2016
NYU School of Medicine
mi
from
New York, NY
Functional Brain Imaging in PTSD
Functional Brain Imaging in PTSD
Status: Enrolling
Updated: 3/2/2016
NYU School of Medicine
mi
from
New York, NY
Click here to add this to my saved trials
Research Study of Treatment for Winter Depression With Different Colors of Light
Optimizing Light Wavelength for Treatment of Seasonal Affective Disorder
Status: Enrolling
Updated:  3/2/2016
Thomas Jefferson University
mi
from
Philadelphia, PA
Research Study of Treatment for Winter Depression With Different Colors of Light
Optimizing Light Wavelength for Treatment of Seasonal Affective Disorder
Status: Enrolling
Updated: 3/2/2016
Thomas Jefferson University
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Cognitive Behavioral Aggression Treatment
Cognitive Behavioral Aggression Treatment: Effects on Brain and Behavior
Status: Enrolling
Updated:  3/3/2016
Temple University
mi
from
Philadelphia, PA
Cognitive Behavioral Aggression Treatment
Cognitive Behavioral Aggression Treatment: Effects on Brain and Behavior
Status: Enrolling
Updated: 3/3/2016
Temple University
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Optimizing Posttraumatic Stress Disorder Treatment: Prolonged Exposure (PE) Versus PE Plus Sertraline
Optimizing PTSD Treatment: PE Versus PE Plus Sertraline
Status: Enrolling
Updated:  3/3/2016
Psychological Sciences Department Case Western Reserve University
mi
from
Cleveland, OH
Optimizing Posttraumatic Stress Disorder Treatment: Prolonged Exposure (PE) Versus PE Plus Sertraline
Optimizing PTSD Treatment: PE Versus PE Plus Sertraline
Status: Enrolling
Updated: 3/3/2016
Psychological Sciences Department Case Western Reserve University
mi
from
Cleveland, OH
Click here to add this to my saved trials
Optimizing Posttraumatic Stress Disorder Treatment: Prolonged Exposure (PE) Versus PE Plus Sertraline
Optimizing PTSD Treatment: PE Versus PE Plus Sertraline
Status: Enrolling
Updated:  3/3/2016
Psychology Department of University of Washington
mi
from
Seattle, WA
Optimizing Posttraumatic Stress Disorder Treatment: Prolonged Exposure (PE) Versus PE Plus Sertraline
Optimizing PTSD Treatment: PE Versus PE Plus Sertraline
Status: Enrolling
Updated: 3/3/2016
Psychology Department of University of Washington
mi
from
Seattle, WA
Click here to add this to my saved trials
Omega-3 and Therapy Study for Childhood Bipolar Disorder- Not Otherwise Specified
Omega-3 Fatty Acids & Psychoeducational Psychotherapy for Childhood Bipolar Disorder- Not Otherwise Specified
Status: Enrolling
Updated:  3/4/2016
Ohio State University Medical Center - Harding Hospital
mi
from
Columbus, OH
Omega-3 and Therapy Study for Childhood Bipolar Disorder- Not Otherwise Specified
Omega-3 Fatty Acids & Psychoeducational Psychotherapy for Childhood Bipolar Disorder- Not Otherwise Specified
Status: Enrolling
Updated: 3/4/2016
Ohio State University Medical Center - Harding Hospital
mi
from
Columbus, OH
Click here to add this to my saved trials
Effectiveness of the Quotient® ADHD Assessment in a System of Care
Effectiveness of the Quotient® ADHD Assessment in a System of Care
Status: Enrolling
Updated:  3/4/2016
Kaiser Permanente, Folsom
mi
from
Folsom, CA
Effectiveness of the Quotient® ADHD Assessment in a System of Care
Effectiveness of the Quotient® ADHD Assessment in a System of Care
Status: Enrolling
Updated: 3/4/2016
Kaiser Permanente, Folsom
mi
from
Folsom, CA
Click here to add this to my saved trials
Effectiveness of the Quotient® ADHD Assessment in a System of Care
Effectiveness of the Quotient® ADHD Assessment in a System of Care
Status: Enrolling
Updated:  3/4/2016
Kaiser Permanente Roseville
mi
from
Roseville, CA
Effectiveness of the Quotient® ADHD Assessment in a System of Care
Effectiveness of the Quotient® ADHD Assessment in a System of Care
Status: Enrolling
Updated: 3/4/2016
Kaiser Permanente Roseville
mi
from
Roseville, CA
Click here to add this to my saved trials
Effectiveness of the Quotient® ADHD Assessment in a System of Care
Effectiveness of the Quotient® ADHD Assessment in a System of Care
Status: Enrolling
Updated:  3/4/2016
Kaiser Permanente, Walnut Creek Medical Center
mi
from
Walnut Creek, CA
Effectiveness of the Quotient® ADHD Assessment in a System of Care
Effectiveness of the Quotient® ADHD Assessment in a System of Care
Status: Enrolling
Updated: 3/4/2016
Kaiser Permanente, Walnut Creek Medical Center
mi
from
Walnut Creek, CA
Click here to add this to my saved trials
Multiple Ascending Dose Study on Safety, Tolerability, and Pharmacokinetics of AMG 581 in Healthy Subjects or Subjects With Schizophrenia or Schizoaffective
A Phase I, Randomized, Placebo-controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of AMG 581 in Healthy Subjects or Subjects With Schizophrenia or Schizoaffective Disorder on Antipsychotic Medication
Status: Enrolling
Updated:  3/4/2016
Clinical Research Facility
mi
from
Glendale, CA
Multiple Ascending Dose Study on Safety, Tolerability, and Pharmacokinetics of AMG 581 in Healthy Subjects or Subjects With Schizophrenia or Schizoaffective
A Phase I, Randomized, Placebo-controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of AMG 581 in Healthy Subjects or Subjects With Schizophrenia or Schizoaffective Disorder on Antipsychotic Medication
Status: Enrolling
Updated: 3/4/2016
Clinical Research Facility
mi
from
Glendale, CA
Click here to add this to my saved trials